S&P 500   5,251.59 (+0.06%)
DOW   39,764.85 (+0.01%)
QQQ   444.25 (-0.13%)
AAPL   171.20 (-1.22%)
MSFT   419.89 (-0.37%)
META   486.02 (-1.59%)
GOOGL   150.66 (-0.14%)
AMZN   179.92 (+0.05%)
TSLA   177.64 (-1.22%)
NVDA   907.63 (+0.57%)
NIO   4.61 (-1.28%)
AMD   182.03 (+1.36%)
BABA   72.47 (+1.23%)
T   17.61 (+0.34%)
F   13.21 (+1.15%)
MU   118.10 (-0.87%)
CGC   9.78 (+2.41%)
GE   175.38 (-2.63%)
DIS   122.58 (+1.32%)
AMC   3.70 (-14.75%)
PFE   27.91 (+0.47%)
PYPL   67.53 (+1.44%)
XOM   115.75 (+0.68%)
S&P 500   5,251.59 (+0.06%)
DOW   39,764.85 (+0.01%)
QQQ   444.25 (-0.13%)
AAPL   171.20 (-1.22%)
MSFT   419.89 (-0.37%)
META   486.02 (-1.59%)
GOOGL   150.66 (-0.14%)
AMZN   179.92 (+0.05%)
TSLA   177.64 (-1.22%)
NVDA   907.63 (+0.57%)
NIO   4.61 (-1.28%)
AMD   182.03 (+1.36%)
BABA   72.47 (+1.23%)
T   17.61 (+0.34%)
F   13.21 (+1.15%)
MU   118.10 (-0.87%)
CGC   9.78 (+2.41%)
GE   175.38 (-2.63%)
DIS   122.58 (+1.32%)
AMC   3.70 (-14.75%)
PFE   27.91 (+0.47%)
PYPL   67.53 (+1.44%)
XOM   115.75 (+0.68%)
S&P 500   5,251.59 (+0.06%)
DOW   39,764.85 (+0.01%)
QQQ   444.25 (-0.13%)
AAPL   171.20 (-1.22%)
MSFT   419.89 (-0.37%)
META   486.02 (-1.59%)
GOOGL   150.66 (-0.14%)
AMZN   179.92 (+0.05%)
TSLA   177.64 (-1.22%)
NVDA   907.63 (+0.57%)
NIO   4.61 (-1.28%)
AMD   182.03 (+1.36%)
BABA   72.47 (+1.23%)
T   17.61 (+0.34%)
F   13.21 (+1.15%)
MU   118.10 (-0.87%)
CGC   9.78 (+2.41%)
GE   175.38 (-2.63%)
DIS   122.58 (+1.32%)
AMC   3.70 (-14.75%)
PFE   27.91 (+0.47%)
PYPL   67.53 (+1.44%)
XOM   115.75 (+0.68%)
S&P 500   5,251.59 (+0.06%)
DOW   39,764.85 (+0.01%)
QQQ   444.25 (-0.13%)
AAPL   171.20 (-1.22%)
MSFT   419.89 (-0.37%)
META   486.02 (-1.59%)
GOOGL   150.66 (-0.14%)
AMZN   179.92 (+0.05%)
TSLA   177.64 (-1.22%)
NVDA   907.63 (+0.57%)
NIO   4.61 (-1.28%)
AMD   182.03 (+1.36%)
BABA   72.47 (+1.23%)
T   17.61 (+0.34%)
F   13.21 (+1.15%)
MU   118.10 (-0.87%)
CGC   9.78 (+2.41%)
GE   175.38 (-2.63%)
DIS   122.58 (+1.32%)
AMC   3.70 (-14.75%)
PFE   27.91 (+0.47%)
PYPL   67.53 (+1.44%)
XOM   115.75 (+0.68%)
NASDAQ:CDMO

Avid Bioservices (CDMO) Stock Price, News & Analysis

$6.96
-0.02 (-0.29%)
(As of 12:34 PM ET)
Today's Range
$6.82
$7.11
50-Day Range
$6.09
$8.79
52-Week Range
$4.07
$21.05
Volume
173,076 shs
Average Volume
1.34 million shs
Market Capitalization
$440.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.25

Avid Bioservices MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
104.2% Upside
$14.25 Price Target
Short Interest
Bearish
17.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.96
Upright™ Environmental Score
News Sentiment
0.44mentions of Avid Bioservices in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$31,527 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.06) to $0.15 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.11 out of 5 stars

Medical Sector

193rd out of 939 stocks

Pharmaceutical Preparations Industry

78th out of 435 stocks

CDMO stock logo

About Avid Bioservices Stock (NASDAQ:CDMO)

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries. The company offers various services, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.

CDMO Stock Price History

CDMO Stock News Headlines

Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
CDMO Dec 2024 10.000 call
CDMO Apr 2024 15.000 call
CDMO Dec 2024 2.500 call
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Why Is Avid Bioservices (CDMO) Stock Down 30% Today?
CDMO Mar 2024 7.500 put
Avid Bioservices: Don't Miss The Bigger Picture
See More Headlines
Receive CDMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
6/21/2023
Today
3/28/2024
Next Earnings (Estimated)
4/01/2024
Fiscal Year End
4/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CDMO
Employees
365
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.25
High Stock Price Target
$20.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+104.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$560,000.00
Pretax Margin
-8.22%

Debt

Sales & Book Value

Annual Sales
$149.27 million
Cash Flow
$0.16 per share
Book Value
$3.03 per share

Miscellaneous

Free Float
61,728,000
Market Cap
$440.15 million
Optionable
Optionable
Beta
1.65
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

CDMO Stock Analysis - Frequently Asked Questions

Should I buy or sell Avid Bioservices stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CDMO shares.
View CDMO analyst ratings
or view top-rated stocks.

What is Avid Bioservices' stock price target for 2024?

4 brokerages have issued 1-year price targets for Avid Bioservices' stock. Their CDMO share price targets range from $7.00 to $20.00. On average, they anticipate the company's share price to reach $14.25 in the next year. This suggests a possible upside of 104.2% from the stock's current price.
View analysts price targets for CDMO
or view top-rated stocks among Wall Street analysts.

How have CDMO shares performed in 2024?

Avid Bioservices' stock was trading at $6.50 at the start of the year. Since then, CDMO shares have increased by 7.4% and is now trading at $6.98.
View the best growth stocks for 2024 here
.

Are investors shorting Avid Bioservices?

Avid Bioservices saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 10,840,000 shares, an increase of 64.5% from the February 29th total of 6,590,000 shares. Based on an average daily volume of 1,360,000 shares, the days-to-cover ratio is presently 8.0 days.
View Avid Bioservices' Short Interest
.

When is Avid Bioservices' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024.
View our CDMO earnings forecast
.

How were Avid Bioservices' earnings last quarter?

Avid Bioservices, Inc. (NASDAQ:CDMO) issued its quarterly earnings results on Wednesday, June, 21st. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.07. The biopharmaceutical company had revenue of $39.80 million for the quarter, compared to analyst estimates of $39 million. Avid Bioservices had a negative net margin of 8.12% and a negative trailing twelve-month return on equity of 5.18%. During the same period in the previous year, the company posted $0.04 EPS.

What ETFs hold Avid Bioservices' stock?

ETFs with the largest weight of Avid Bioservices (NASDAQ:CDMO) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE) and Franklin Genomic Advancements ETF (HELX).Invesco S&P SmallCap Health Care ETF (PSCH).

When did Avid Bioservices' stock split?

Avid Bioservices's stock reverse split before market open on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 7th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What guidance has Avid Bioservices issued on next quarter's earnings?

Avid Bioservices issued an update on its third quarter 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $33.8 million-$33.8 million, compared to the consensus revenue estimate of $34.2 million.

What is Roger Lias' approval rating as Avid Bioservices' CEO?

5 employees have rated Avid Bioservices Chief Executive Officer Roger Lias on Glassdoor.com. Roger Lias has an approval rating of 49% among the company's employees. This puts Roger Lias in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 63.0% of employees surveyed would recommend working at Avid Bioservices to a friend.

What other stocks do shareholders of Avid Bioservices own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Micron Technology (MU), QUALCOMM (QCOM), NVIDIA (NVDA), Novavax (NVAX) and Pfizer (PFE).

Who are Avid Bioservices' major shareholders?

Avid Bioservices' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.72%), Vanguard Group Inc. (5.72%), Royal Bank of Canada (3.92%), Palisade Capital Management LP (2.81%), Wellington Management Group LLP (2.34%) and New York State Common Retirement Fund (1.20%). Insiders that own company stock include Daniel R Hart, Gregory Sargen, Joseph Carleone, Mark R Ziebell, Matthew R Kwietniak, Nicholas Stewart Green, Richard A Richieri and Richard B Hancock.
View institutional ownership trends
.

How do I buy shares of Avid Bioservices?

Shares of CDMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CDMO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners